Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis

Romero, Rodrigo, Sayin, Volkan I, Davidson, Shawn M, Bauer, Matthew R, Singh, Simranjit X, LeBoeuf, Sarah E, Karakousi, Triantafyllia R, Ellis, Donald C +20 more·2017·Nature Medicine
DOI 10.1038/nm.4407

Cited by (664)

Items 601–664 of 664

  1. Influence of recipient KRAS gene rs712 polymorphisms on the overall survival rate of hepatocellular carcinoma after hepatic transplantation
    Tiancheng Chu, Rulin Zhang, Xiaolei Liu, Lin Li, Yanning Li, Ziguang Niu, Heng Quan, Yingying Zhao, Yaohua Li · 2024 · Clinical and Experimental Medicine
  2. Modulating T cell metabolism to improve T cell therapy
    Yating Li, Shao-Hsi Hung, Shailbala Singh, Cassian Yee · 2024 · Elsevier eBooks
  3. RASopathy Genes: Germline Risk and Somatic Cancers
    Gina M. Ney, Christian Peter Kratz, Douglas R. Stewart · 2024 · Springer eBooks
  4. Targeting the Undruggable KRAS Mutation in Lung Cancer: A Review
    Clark A. Jones · 2024 · Premier journal of science.
  5. HNF4α controls growth, identity and response to KRAS inhibition of invasive mucinous adenocarcinoma of the lung
    Headtlove Essel Dadzie, Yangsook Song Green, Soledad A. Camolotto, Matthew Gumbleton, Yutaka Maeda, Benjamin T. Spike, Eric L. Snyder · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  6. Targeting Ferroptosis in Tuberous Sclerosis Cell Line Models
    Tasmia Tahsin · 2025
  7. Burkitt’s Lymphoma and Early B Cell Transformation as Paradigms of How Epstein-Barr Virus Overcomes Apoptosis and Ferroptosis
    Georg W. Bornkamm, Gemma L. Kelly, Aisling M. Ross · 2025 · Current topics in microbiology and immunology
  8. Additional file 1 of RUNX3-mediated circDYRK1A inhibits glutamine metabolism in gastric cancer by up-regulating microRNA-889-3p-dependent FBXO4
    Liu, Haofeng, Qiu Xue, Cai, Hongzhou, Jiang, Xiaohui, Cao, Guangxin, Tie Chen, Chen, Yuan, Ding Wang · 2022 · Figshare
  9. Additional file 8 of RUNX3-mediated circDYRK1A inhibits glutamine metabolism in gastric cancer by up-regulating microRNA-889-3p-dependent FBXO4
    Liu, Haofeng, Xue, Qiu, Cai, Hongzhou, Jiang, Xiaohui, Cao, Guangxin, Tie Chen, Chen, Yuan, Ding Wang · 2022 · Figshare
  10. Additional file 2 of RUNX3-mediated circDYRK1A inhibits glutamine metabolism in gastric cancer by up-regulating microRNA-889-3p-dependent FBXO4
    Liu, Haofeng, Xue, Qiu, Cai, Hongzhou, Jiang, Xiaohui, Cao, Guangxin, Tie Chen, Chen, Yuan, Ding Wang · 2022 · Figshare
  11. Additional file 6 of RUNX3-mediated circDYRK1A inhibits glutamine metabolism in gastric cancer by up-regulating microRNA-889-3p-dependent FBXO4
    Liu, Haofeng, Xue, Qiu, Cai, Hongzhou, Jiang, Xiaohui, Cao, Guangxin, Tie Chen, Chen, Yuan, Ding Wang · 2022 · Figshare
  12. Additional file 3 of RUNX3-mediated circDYRK1A inhibits glutamine metabolism in gastric cancer by up-regulating microRNA-889-3p-dependent FBXO4
    Liu, Haofeng, Qiu Xue, Cai, Hongzhou, Jiang, Xiaohui, Cao, Guangxin, Tie Chen, Chen, Yuan, Ding Wang · 2022 · Figshare
  13. Additional file 7 of RUNX3-mediated circDYRK1A inhibits glutamine metabolism in gastric cancer by up-regulating microRNA-889-3p-dependent FBXO4
    Liu, Haofeng, Xue, Qiu, Cai, Hongzhou, Jiang, Xiaohui, Cao, Guangxin, Tie Chen, Chen, Yuan, Ding Wang · 2022 · Figshare
  14. Additional file 2 of Prediction of metabolites associated with somatic mutations in cancers by using genome-scale metabolic models and mutation data
    GaRyoung Lee, Sang Mi Lee, Lee, Sungyoung, Jeong, Chang Wook, Hyojin Song, Lee, Sang Yup, Yun, Hongseok, Koh, Youngil, Kim, Hyun Uk · 2024 · Figshare
  15. Additional file 5 of RUNX3-mediated circDYRK1A inhibits glutamine metabolism in gastric cancer by up-regulating microRNA-889-3p-dependent FBXO4
    Liu, Haofeng, Xue, Qiu, Cai, Hongzhou, Jiang, Xiaohui, Cao, Guangxin, Tie Chen, Chen, Yuan, Ding Wang · 2022 · Figshare
  16. Additional file 4 of RUNX3-mediated circDYRK1A inhibits glutamine metabolism in gastric cancer by up-regulating microRNA-889-3p-dependent FBXO4
    Liu, Haofeng, Xue, Qiu, Cai, Hongzhou, Jiang, Xiaohui, Cao, Guangxin, Tie Chen, Chen, Yuan, Ding Wang · 2022 · Figshare
  17. Additional file 2 of Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma
    Tongyan Liu, Han, Chencheng, Panqi Fang, Ma, Zhifei, Wang, Xiaoxiao, Chen, Hao, Siwei Wang, Meng, Fanchen, Wang, Cheng, Erbao Zhang et al. · 2022 · Figshare
  18. Additional file 1 of Prediction of metabolites associated with somatic mutations in cancers by using genome-scale metabolic models and mutation data
    GaRyoung Lee, Sang Mi Lee, Lee, Sungyoung, Jeong, Chang Wook, Hyojin Song, Lee, Sang Yup, Yun, Hongseok, Koh, Youngil, Kim, Hyun Uk · 2024 · Figshare
  19. Additional file 2 of E3 ligase TRIM15 facilitates non-small cell lung cancer progression through mediating Keap1-Nrf2 signaling pathway
    Liang Manman, Wang, Lijing, Zhengui Sun, Xingwu Chen, Wang, Hanli, Lilong Qin, Zhao, Wenying, Biao Geng · 2022 · Figshare
  20. Zero-shot biological reasoning with open-weights large language models reproduces CRISPR screen based prediction of synthetic lethal interactions
    A. Prosz, Z. Sztupinszki, M. Dióssy, O. Kilim, Bogumił Zimoń, I. Csabai, Z. Szallasi · 2026 · bioRxiv
  21. Genomic alterations and their correlation with metabolic-related genes in lung cancer
    Gauri Gaur, Niraj Kumar Jha, Lokesh Gambhir, Seema V. Acharya, Dhruv Kumar · 2026 · Clinical & Translational Oncology
  22. Design, synthesis and biological evaluation of symmetric thiadiazole carboxamide derivative as glutaminase inhibitor
    Rajath Cyriac, Eun Ji Lee, Yeongju Kwon, Mi Ran Yun, Myoung Eun Jung, Sunjoo Ahn, Chang Hak Chae, Gildon Choi, Byoung Chul Cho, Kwangho Lee · 2026 · Bioorganic & Medicinal Chemistry Letters
  23. Low doses of ascorbic acid modulate the effect of chemotherapy agents in sarcoma 180 tumor-bearing mice
    Josemar José da Silva Júnior, Leonardo da Rocha Sousa, Victor Alves de Oliveira, Antônio Lima Braga, Ag-Anne Pereira Melo de Meneses, Ricardo Melo de Carvalho, Joedna Cavalcante Pereira, Reyca Rodrigues e Silva, Raí Pablo Sousa de Aguiar, Antonielly Campinho dos Reis et al. · 2026 · Mutation Research/Genetic Toxicology and Environmental Mutagenesis
  24. Targeting ubiquitin signaling vulnerabilities in KEAP1-inactivated lung cancer
    Varun Jayeshkumar Shah, Oliver Hartmann, Martin Wegner, Cristian Prieto‐Garcia, Rubina S. Kazi, Viktoria von Heyl zu Herrnsheim, Amin Wanli, Igor Mačinković, Bianka Bohnacker, Koraljka Husnjak et al. · 2026 · The EMBO Journal
  25. Potential oncogenic risks of Keap1-targeting PROTACs: Caution warranted in drug design
    Zi-Ming Zhao, Wen Ma, Jincen Hao, Gaofei Hu, Xinfeng Wang · 2026 · Acta Pharmaceutica Sinica B
  26. A proteomic approach for understanding the metabolic adaptations in non-small cell lung cancer
    Alfonso Martín-Bernabé · 2018 · theses.fr (ABES)
  27. Les protéines ING2 et ING3 : identification de nouvelles fonctions et implication en cancérologie
    Charles Ricordel · 2022
  28. Drowning in cysteine
    Alec J. Vaughan, Thales Y. Papagiannakopoulos · 2026 · Nature Metabolism
  29. Chronic arsenic exposure promotes cell migration via KEAP1-mediated F-actin cytoskeletal rearrangement
    Xin Fang, Junyi Wang, Xianhang Yin, Maojia Fu, Yuxin Hu, Huihui Wang, Jingbo Pi, Yuanyuan Xu · 2026 · Toxicology and Applied Pharmacology
  30. Identification of Combinatorial Targets for Anticancer Drug Discovery
    Min Huang, Meiyu Geng · 2026 · 中国科学基金
  31. HNF4α controls growth, identity, and KRAS inhibitor response in invasive mucinous adenocarcinoma of the lung
    Headtlove Essel Dadzie, Yangsook Song Green, Soledad A. Camolotto, Henry U. Arnold, Matthew Gumbleton, Minzhe Guo, Mari A. Mino-Kenudson, Yutaka Maeda, Benjamin T. Spike, Eric L. Snyder · 2026 · Journal of Clinical Investigation
  32. Sijunzi Decoction Reverses Metabolic Adaptation and Induces Ferroptosis in Cisplatin-Resistant Non–small Cell Lung Cancer: An Integrative Metabolomics–Pharmacology Analysis
    Wenjun Liu, Han-yu Dong, Liu Chun-ying, Chun Wang · 2026 · Current Medical Science
  33. Two Failure Modes of Glutathione Homeostasis: A Calibrated Dynamical Model Recovers G6PD Severe-Deficiency Contraindications and Forecasts a Phase II NSCLC Trial Outcome
    Daniel Murray · 2026 · SSRN Electronic Journal
  34. ALDH18A1 regulates glutamine metabolism and tumor microenvironment in the attenuation of clear cell renal cell carcinoma
    Yang Fu, Xuzhong Liu, Qing Sun, Zhiwang Tang, Zongyuan Xu, Kun Liu · 2026 · Cancer Cell International
  35. Therapeutic potential of drug repurposing in reversing chemoresistance
    Vivek Panwar, Aarushi Rana - · 2026 · Elsevier eBooks
  36. Discovery of ferroptosis-inducing R4VP compounds for targeting aggressive cancers
    Avital Oknin-Vaisman, Deepanjan Panda, Rostislav Novak, Ghazal Kheshaiboun, Eliya Bitman-Lotan, Satish Gandhesiri, Rubina S. Kazi, Nikolett Pahor, Viktoria von Heyl zu Herrnsheim, Yamen Abu Ahmad et al. · 2026 · Oncogene
  37. Beyond KEAP1: The Context-Specific NRF2 Partner Code in Disease and Therapy
    Seung-Jin Kwag, Jin‐Kwon Lee, Seung-Jun Lee, Jae-Min Hwang, Young‐Sool Hah · 2026 · Antioxidants
  38. Clinical Outcomes Associated with Single STK11 Mutations and Those Co-occurring with KEAP1 and KRAS Mutations in Metastatic Non-Small Cell Lung Cancer
    Firas Dabbous, Mehmet BERKTAŞ, Rajrupa Ghosh, Samuel Huse, Ching-Yu Wang, Ashish Gautam, Kazeem Idowu, Daniel Simmons, Puneeth Iyengar · 2026 · Advances in Therapy
  39. A dynamical model of glutathione homeostasis in G6PD deficiency and NRF2-activated non-small cell lung cancer
    Daniel John Murray · 2026 · Redox Biochemistry and Chemistry
  40. Feasibility Study of Intratumoral NRF2 Expression as a Predictive Biomarker for the Effectiveness of Immunotherapy in Patients with Non-Small Cell Lung Cancer Treated with PD-1 Inhibitor
    Yasuto Jin, Yukihisa Inoue, Hiroyuki Shimada, Tetsu Hara, Shohei Yamashita, Mio Yamamoto, Osamu Matsubara · 2026 · Cancers
  41. The Interdependence of Carbon Substrates and Metabolic Pathways Enables the Metabolic Plasticity of Cancer Cells
    Inês Serpa-Gonçalves, Jacinta Serpa · 2026 · Advances in experimental medicine and biology
  42. Tumoral Metabolism at the Intersection of Oncogene Signaling, Epigenetics and Immunology: Emerging Therapeutic Strategies in Cancer
    Bhoomendra A. Bhongade, Areeg Anwer Ali, Mohamed El‐Tanani, Shakta Mani Satyam, Sirajunisa Talath, Adil Farooq Wali, Syed Arman Rabbani, Walaa Ibraheem, Karolina Hoffmann, Авагимян Ашот Арманович et al. · 2026 · Current Issues in Molecular Biology
  43. Metabolic control of ferroptosis in cancer: lipid dependencies as therapeutic vulnerabilities
    Anna Di Dio, Gerardina Smaldone, Valeria Napolitano, Alessia Bertamino, Isabel Maria Gomez-Monterrey · 2026 · Frontiers in Oncology
  44. Proteogenomic characterization of pulmonary large-cell neuroendocrine carcinoma identifies molecular features and therapeutic strategy
    Lele Zhang, Liangdong Sun, Shengnan Duan, Yilv Yan, Jinyi Song, Linghui Xia, Huansha Yu, Jijun Sun, Junjie Hu, Di Wang et al. · 2026 · Science Advances
  45. Spatial ecotype in tumor immune exclusion: from spatial architecture to therapeutic strategies
    Ming Ying, Lei Zhang, Mengwei Jia, Xiaofei Sun, Yibo Su, Chengcheng Liu, Ming Gong, Tao Sun, Bin Zhang · 2026 · Molecular Cancer
  46. The Redox Imbalance in Cancer: Targeting Glutathione and Thioredoxin Systems to Enhance Chemotherapy Response
    Seerwan Hamadameen Sulaiman, Hemn A.H. Barzani, Rebaz Anwar Omer, Amjad Mahmood Qadir, Ali Abdulhameed Saeed · 2026 · SN Comprehensive Clinical Medicine
  47. Unraveling the role of glutamine metabolism in cancer: from cell death mechanisms to tumor microenvironment modulation
    Xintong Peng, Shuang Liu, Yongguang Tao · 2026 · Experimental Hematology and Oncology
  48. Targeting metabolic reprogramming in cancer: Past, present, and future
    Niti Kumari, Surendra Kumar Shukla, Ravi Thakur · 2026 · Pharmacology & Therapeutics
  49. KRAS/ERK2-driven stabilization of AARS1 reprograms tumor metabolism and confers Sorafenib resistance in lung adenocarcinoma
    Wenxuan Hu, Zhike Chen, Jian Yang, Gaomeng Luo, Haoyang Yuan, Kang Hu, Xin Lv, Yin Wang, Jun Zhao, Chun Xu · 2026 · Cell Death and Differentiation
  50. Exploiting tumor amino acid metabolic heterogeneity: Biological principles and precision nanomedicine
    Dandan Shao, Jie Song, Jianming Wang · 2026 · Nano Today
  51. Subtype-Conditioned NRF2–KEAP1 Signaling in Breast Cancer: A Narrative Review and Hypothesis-Generating Framework from Chemoprevention to Therapy Resistance
    Hye Young Choi, Hayeong Kwon, Young‐Sool Hah · 2026 · Antioxidants
  52. Crosstalk Between Nrf2 and Metabolic Pathways: Redox Regulation, Glutaminolysis, and Cellular Proliferation
    Rademene Sunday Oria, Vivian Amarachukwu Umeano, Victoria Onyemachi CHUKWU, Happiness Ochi Inyang, Saviour God’swealth Usin · 2026 · Cell Biochemistry and Biophysics
  53. Cancer degronopathies and protein-fate biomarkers in drug resistance and cancer progression: signalling mechanisms, measurement and translational limits
    Jiaxin Li, Shuhan Liu, Lu Fu, Qifu Bo, Yujie Bai, Xiangpeng Dai · 2026 · Frontiers in Cell and Developmental Biology
  54. Tumor cell–intrinsic stress states drive sensitivity to CAR T cell therapy in pancreatic cancer
    Julia Fröse, Evelyn Chen, Charles A. Whittaker, Paul Leclerc, Sean Doherty, Adam Langenbucher, Jasmine Shao, Riley D. Hellinger, Daniel R. Goulet, Tuomas Tammela et al. · 2026 · Science Advances
  55. Variant-informed multimodal tissue-state modeling reveals an NRF2 stress niche and dependency axis in KEAP1/NFE2L2-altered cancer
    Mo-Wei Kong, Qiu-Ting Li, Xing-Wei Zhao, Yu Wang, Ya-Mei Luo, Yang Yu, Chun-Xiang Zhang · 2026 · Frontiers in Immunology
  56. Lung cancer metabolism: a dynamic and adaptive network
    Sara Gholamhosseinian Najjar, Christian Frezza · 2026 · Cellular and Molecular Life Sciences
  57. Adaptive Mitochondrial Specialization in Lung Adenocarcinoma: Redox Homeostasis, Hypoxia Adaptation, and Therapeutic Resistance
    Manuel de Jesús Castillejos-López, Ulises Barrera-Elizalde, Edgar Flores‐Soto, L.A. Colín-Godínez, Luz María Torres Espíndola, Bianca S. Romero-Martínez, Joel Guzmán-Castillo, Georgina González-Ávila, Erika Rubí Luis‐García, Fausto Rojas-Durán et al. · 2026 · Antioxidants
  58. Sinensetin Induces Oxidative Stress‐Mediated Apoptosis in Non‐Small Cell Lung Cancer Cells by Suppressing Nrf2/ARE‐Dependent Antioxidant Defense
    Li Junyan, Ruoyun He, 何佳珂, Jian Ye, Yu Xie, Binfan Yuan · 2026 · Journal of Biochemical and Molecular Toxicology
  59. BindingDB Entry 50008027: Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
    BindingDB · 2021 · UC San Diego
  60. BindingDB Entry 50010105: Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Inhibition: An Emerging Strategy in Cancer Therapy.
    BindingDB · 2021 · UC San Diego
  61. BindingDB Entry 50018122: Novel allosteric glutaminase 1 inhibitors with macrocyclic structure activity relationship analysis.
    BindingDB · 2024 · UC San Diego
  62. BindingDB Entry 50011564: Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties.
    BindingDB · 2022 · UC San Diego
  63. Cancer cells acquire cysteine directly from a reduced tumor microenvironment
    Feroza K. Choudhury, Basma A. Yasseen, Paloma González‐Sánchez, Matthew Long, Samantha Caldwell, Pritin N. Soni, Suehelay Acevedo‐Acevedo, Yun Huang, Elsa Renee Flores, Chang Jiang et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  64. Adaptive Rewiring of Nucleotide Metabolism in Therapeutic Resistance
    Bengisu Dayanc, Ganfei Xu, Xiaoshu Zhou, Jinpeng Chen, Noah Mueller, Harsimran Kaur, Breanna Pham, Satoshi Yoda, Jaime Laurel Schneider · 2026 · Cancers